View Financial HealthInfant Bacterial Therapeutics 배당 및 자사주 매입배당 기준 점검 0/6Infant Bacterial Therapeutics 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률n/a자사주 매입 수익률총 주주 수익률n/a미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Mar 31Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 07, 2026Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 07, 2026, at 16:00 W. Europe Standard Time. Location: convendum, fleminggatan 18, stockholm Sweden공시 • Feb 06+ 2 more updatesInfant Bacterial Therapeutics AB (publ) to Report Fiscal Year 2025 Final Results on Mar 27, 2026Infant Bacterial Therapeutics AB (publ) announced that they will report fiscal year 2025 final results at 7:30 AM, Central European Standard Time on Mar 27, 2026공시 • Nov 13+ 1 more updateInfant Bacterial Therapeutics AB (publ) to Report First Half, 2026 Results on Aug 25, 2026Infant Bacterial Therapeutics AB (publ) announced that they will report first half, 2026 results on Aug 25, 2026공시 • May 07Infant Bacterial Therapeutics AB (publ) to Report Fiscal Year 2025 Results on Feb 06, 2026Infant Bacterial Therapeutics AB (publ) announced that they will report fiscal year 2025 results at 8:00 AM, Central European Standard Time on Feb 06, 2026공시 • Apr 24Infant Bacterial Therapeutics to Present Results of the Connection Study at Las 2025 in HawaiiInfant Bacterial Therapeutics (IBT) announced that results from its pivotal Phase III trial, "The Connection Study," will be presented at the Pediatric Academic Societies (PAS) 2025 Annual Meeting in Honolulu, Hawaii, on April 26, 2025. Both the oral and poster presentations will take place at the Hawaii Convention Center and will be delivered by Prof. Josef Neu, Principal Investigator of the study and Professor of Pediatrics at the University of Florida. The PAS 2025 Meeting, held from is a premier international forum for pediatric April 24-28, researchers, clinicians, and educators. IBT's presentations will spotlight findings from its investigational therapeutic IBP-9414, a live biotherapeutic product designed to prevent necrotizing enterocolitis (NEC) and reduce all-cause mortality in preterm infants.공시 • Apr 08Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2025Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2025, at 16:00 W. Europe Standard Time. Location: at wetmanska palatset, conference room, bryggarkungen, hollandargatan 17, stockholm Sweden공시 • Nov 14+ 2 more updatesInfant Bacterial Therapeutics AB (publ) to Report Q3, 2025 Results on Nov 13, 2025Infant Bacterial Therapeutics AB (publ) announced that they will report Q3, 2025 results at 8:30 AM, Central European Standard Time on Nov 13, 2025공시 • Oct 09Infant Bacterial Therapeutics AB (Publ) Announces the Appointment of the Nomination Committee for the Annual General Meeting 2025Infant Bacterial Therapeutics AB (publ) announced that the Nomination Committee for the Annual General Meeting 2025 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of David Dangoor (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who through direct and indirect ownership is the company's second largest shareholder, and Jannis Kitsakis, appointed by the third largest shareholder, Fjärde AP-fonden. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board.공시 • Aug 31Infant Bacterial Therapeutics Announces Results of Phase III Study Shows No Significant Effects on the Primary EndpointsInfant Bacterial Therapeutics has conducted a phase III study comprising 2153 premature infants for five years. The objective of the study has been to show that the company's drug candidate IBP-9414, a bacterial strain found naturally in human breast milk, can improve the health of premature infants by preventing necrotizing enterocolitis (NEC) and improve premature infants' gastrointestinal function (measured as time to Sustained Feeding Tolerance, SFT) and, as a secondary objective, reduce death. The results of the study have now been analyzed according to the pre-specified statistical analysis plan. Although these analysis showed positive trends, there were no statistical significance for the two primary endpoints: prevention of necrotizing enterocolitis (NEC), active group: 8.7% vs placebo group: 10.2% (p=0.24) and SFT, active group: 16 days vs placebo group: 17 days (p=0.07). Importantly, there was a significant reduction in the secondary endpoint of all-cause mortality, active group: 6.2% vs placebo group: 8.5% (p=0.04), corresponding to a significant risk reduction of 27%, which meant that in reality 23 infants' lives were spared by the administration of IBP-9414 in the study. IBT will continue the development towards pharmaceutical registration, considering that the study showed statistical significance on all-cause mortality. The previous communicated timeline for the registration might be affected and IBT will revert with an update if any changes will occur. The risk reduction of 27% in mortality is a substantial effect size and comparable to currently available pharmaceutical products, for example, surfactants used in the neonatal intensive care units. The effect of IBP-9414 could potentially save the lives of thousands of infants per year and is the only Live Biopharmaceutical candidate that has shown a strong advantage in saving premature infants' lives. Furthermore the study shows that giving IBP-9414 to these very vulnerable premature infants does not cause any safety issues, including the risk of sepsis which has been a concern expressed by the FDA for the use of probiotic products in preterm infants.공시 • Mar 26+ 1 more updateInfant Bacterial Therapeutics AB (publ) to Report Nine Months, 2024 Results on Nov 14, 2024Infant Bacterial Therapeutics AB (publ) announced that they will report nine months, 2024 results on Nov 14, 2024공시 • Aug 26Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2024Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2024, at 16:00 Central European Standard Time.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 IFTB.F 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: IFTB.F 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Infant Bacterial Therapeutics 배당 수익률 vs 시장IFTB.F의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (IFTB.F)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Pharmaceuticals)2.1%분석가 예측 (IFTB.F) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 IFTB.F 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 IFTB.F 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 IFTB.F 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: IFTB.F 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/19 14:10종가2026/02/19 00:00수익2026/03/31연간 수익2025/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Infant Bacterial Therapeutics AB (publ)는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Mar 31Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 07, 2026Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 07, 2026, at 16:00 W. Europe Standard Time. Location: convendum, fleminggatan 18, stockholm Sweden
공시 • Feb 06+ 2 more updatesInfant Bacterial Therapeutics AB (publ) to Report Fiscal Year 2025 Final Results on Mar 27, 2026Infant Bacterial Therapeutics AB (publ) announced that they will report fiscal year 2025 final results at 7:30 AM, Central European Standard Time on Mar 27, 2026
공시 • Nov 13+ 1 more updateInfant Bacterial Therapeutics AB (publ) to Report First Half, 2026 Results on Aug 25, 2026Infant Bacterial Therapeutics AB (publ) announced that they will report first half, 2026 results on Aug 25, 2026
공시 • May 07Infant Bacterial Therapeutics AB (publ) to Report Fiscal Year 2025 Results on Feb 06, 2026Infant Bacterial Therapeutics AB (publ) announced that they will report fiscal year 2025 results at 8:00 AM, Central European Standard Time on Feb 06, 2026
공시 • Apr 24Infant Bacterial Therapeutics to Present Results of the Connection Study at Las 2025 in HawaiiInfant Bacterial Therapeutics (IBT) announced that results from its pivotal Phase III trial, "The Connection Study," will be presented at the Pediatric Academic Societies (PAS) 2025 Annual Meeting in Honolulu, Hawaii, on April 26, 2025. Both the oral and poster presentations will take place at the Hawaii Convention Center and will be delivered by Prof. Josef Neu, Principal Investigator of the study and Professor of Pediatrics at the University of Florida. The PAS 2025 Meeting, held from is a premier international forum for pediatric April 24-28, researchers, clinicians, and educators. IBT's presentations will spotlight findings from its investigational therapeutic IBP-9414, a live biotherapeutic product designed to prevent necrotizing enterocolitis (NEC) and reduce all-cause mortality in preterm infants.
공시 • Apr 08Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2025Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2025, at 16:00 W. Europe Standard Time. Location: at wetmanska palatset, conference room, bryggarkungen, hollandargatan 17, stockholm Sweden
공시 • Nov 14+ 2 more updatesInfant Bacterial Therapeutics AB (publ) to Report Q3, 2025 Results on Nov 13, 2025Infant Bacterial Therapeutics AB (publ) announced that they will report Q3, 2025 results at 8:30 AM, Central European Standard Time on Nov 13, 2025
공시 • Oct 09Infant Bacterial Therapeutics AB (Publ) Announces the Appointment of the Nomination Committee for the Annual General Meeting 2025Infant Bacterial Therapeutics AB (publ) announced that the Nomination Committee for the Annual General Meeting 2025 has been formed in accordance with the decision of the Annual General Meeting. The Nomination Committee consists of David Dangoor (Chairman of the Nomination Committee), appointed by the largest shareholder Annwall & Rothschild Investments AB, Sebastian Jahreskog, who through direct and indirect ownership is the company's second largest shareholder, and Jannis Kitsakis, appointed by the third largest shareholder, Fjärde AP-fonden. In addition, Peter Rothschild is a member of the Nomination Committee in his capacity as Chairman of the Board.
공시 • Aug 31Infant Bacterial Therapeutics Announces Results of Phase III Study Shows No Significant Effects on the Primary EndpointsInfant Bacterial Therapeutics has conducted a phase III study comprising 2153 premature infants for five years. The objective of the study has been to show that the company's drug candidate IBP-9414, a bacterial strain found naturally in human breast milk, can improve the health of premature infants by preventing necrotizing enterocolitis (NEC) and improve premature infants' gastrointestinal function (measured as time to Sustained Feeding Tolerance, SFT) and, as a secondary objective, reduce death. The results of the study have now been analyzed according to the pre-specified statistical analysis plan. Although these analysis showed positive trends, there were no statistical significance for the two primary endpoints: prevention of necrotizing enterocolitis (NEC), active group: 8.7% vs placebo group: 10.2% (p=0.24) and SFT, active group: 16 days vs placebo group: 17 days (p=0.07). Importantly, there was a significant reduction in the secondary endpoint of all-cause mortality, active group: 6.2% vs placebo group: 8.5% (p=0.04), corresponding to a significant risk reduction of 27%, which meant that in reality 23 infants' lives were spared by the administration of IBP-9414 in the study. IBT will continue the development towards pharmaceutical registration, considering that the study showed statistical significance on all-cause mortality. The previous communicated timeline for the registration might be affected and IBT will revert with an update if any changes will occur. The risk reduction of 27% in mortality is a substantial effect size and comparable to currently available pharmaceutical products, for example, surfactants used in the neonatal intensive care units. The effect of IBP-9414 could potentially save the lives of thousands of infants per year and is the only Live Biopharmaceutical candidate that has shown a strong advantage in saving premature infants' lives. Furthermore the study shows that giving IBP-9414 to these very vulnerable premature infants does not cause any safety issues, including the risk of sepsis which has been a concern expressed by the FDA for the use of probiotic products in preterm infants.
공시 • Mar 26+ 1 more updateInfant Bacterial Therapeutics AB (publ) to Report Nine Months, 2024 Results on Nov 14, 2024Infant Bacterial Therapeutics AB (publ) announced that they will report nine months, 2024 results on Nov 14, 2024
공시 • Aug 26Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2024Infant Bacterial Therapeutics AB (publ), Annual General Meeting, May 08, 2024, at 16:00 Central European Standard Time.